Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

by Yesim Aydinok, Antonis Kattamis, M. Domenica Cappellini, Amal El-Beshlawy, Raffaella Origa, Mohsen Elalfy, Yurdanur Kilinç, Silverio Perrotta, Zeynep Karakas, Vip Viprakasit, Dany Habr, Niculae Constantinovici, Junwu Shen, John B. Porter
Published 2018

Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major

by Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi Kong Li, Vip Viprakasit, Mohsen S. Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher
Published 2018

Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload

by Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi Kong Li, Vip Viprakasit, Mohsen Saleh Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher
Published 2018

Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

by Maria Domenica Cappellini, John Porter, Amal El-Beshlawy, Chi Kong Li, John F. Seymour, Mohsen Elalfy, Norbert Gattermann, Stéphane Giraudier, Jong Wook Lee, Lee Lee Chan, Kai Hsin Lin, Christian Rose, Ali Taher, Swee Lay Thein, Vip Viprakasit, Dany Habr, Gabor Domokos, Bernard Roubert, Antonis Kattamis
Published 2018